A detailed history of Price T Rowe Associates Inc transactions in Geron Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,064,963 shares of GERN stock, worth $9.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,064,963
Previous 187,779 999.68%
Holding current value
$9.35 Million
Previous $397,000 1616.62%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.75 - $3.44 $3.29 Million - $6.46 Million
1,877,184 Added 999.68%
2,064,963 $6.82 Million
Q4 2023

Feb 14, 2024

BUY
$1.74 - $2.31 $28,711 - $38,117
16,501 Added 9.63%
187,779 $397,000
Q3 2023

Nov 14, 2023

SELL
$2.11 - $3.28 $134,734 - $209,444
-63,855 Reduced 27.16%
171,278 $364,000
Q2 2023

Aug 14, 2023

BUY
$1.97 - $3.69 $156,264 - $292,698
79,322 Added 50.91%
235,133 $755,000
Q1 2023

May 15, 2023

SELL
$2.14 - $3.4 $95,799 - $152,204
-44,766 Reduced 22.32%
155,811 $339,000
Q4 2022

Feb 14, 2023

SELL
$2.03 - $2.42 $5,507 - $6,565
-2,713 Reduced 1.33%
200,577 $485,000
Q3 2022

Nov 14, 2022

BUY
$1.67 - $2.94 $36,755 - $64,706
22,009 Added 12.14%
203,290 $476,000
Q2 2022

Aug 15, 2022

BUY
$1.19 - $1.65 $8,259 - $11,452
6,941 Added 3.98%
181,281 $281,000
Q1 2022

May 16, 2022

BUY
$0.99 - $1.6 $7,293 - $11,787
7,367 Added 4.41%
174,340 $237,000
Q4 2021

Feb 14, 2022

SELL
$1.22 - $1.72 $6,832 - $9,632
-5,600 Reduced 3.25%
166,973 $204,000
Q3 2021

Nov 15, 2021

BUY
$1.2 - $1.5 $3,411 - $4,264
2,843 Added 1.68%
172,573 $236,000
Q2 2021

Aug 16, 2021

BUY
$1.25 - $1.83 $4,443 - $6,505
3,555 Added 2.14%
169,730 $239,000
Q1 2021

May 17, 2021

SELL
$1.52 - $2.1 $44,508 - $61,492
-29,282 Reduced 14.98%
166,175 $263,000
Q4 2020

Feb 16, 2021

BUY
$1.55 - $2.05 $302,958 - $400,686
195,457 New
195,457 $311,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.71B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.